PRTA stock exhibits high volatility, reflecting the binary nature of clinical-stage biopharmaceutical development. Regulatory updates, trial data readouts, and partner announcements frequently trigger substantial percentage swings in its share price that outpace broader market index movements.
The Chief Executive Officer of Adthena (an enterprise-grade competitive intelligence and search marketing platform) is Phillip Thune, who took over executive leadership to steer the company's global product scaling, market expansion, and advanced AI-...
Prothena was officially founded in late 2012 as a corporate spin-off from Elan Corporation, inheriting a rich legacy of pioneering neuroscience research.
Prothena Corporation operates as a late-stage clinical biotechnology enterprise focused on the discovery, development, and commercialization of novel precision immunotherapies.
Prothena's primary competitive landscape consists of biotechnology companies developing precision immunotherapies and disease-modifying treatments for neurodegeneration and protein misfolding, including specialized firms like Anavex Life Sciences, AC...
Prothena Corporation PLC (NASDAQ: PRTA) is a late-stage clinical-stage biotechnology enterprise focused on the discovery and development of novel precision therapeutics for protein dysregulation, neurodegenerative disorders (such as Alzheimer's and P...
Yes, Prothena Corporation PLC (NASDAQ: PRTA) underwent a historic corporate stock adjustment structure, while its historical precursor entity (Protara Therapeutics, formerly TARA) executed a notable 1-for-40 reverse stock split to comply with major e...
The President and Chief Executive Officer (CEO) of Prothena Corporation is Dr. Gene G. Kinney, who has led the executive management team and served in various senior scientific and operational roles within the organization.
Evaluating whether a clinical-stage biotechnology stock is a suitable purchase requires careful analysis of upcoming pipeline clinical data readouts, cash burn runway, and regulatory approval milestones.
Prothena Corporation operates with a streamlined, specialized team of approximately 67 full-time employees, reflecting a lean clinical-stage biopharmaceutical operating model that partners with larger global pharmaceutical giants for extensive late-s...
No, Prothena Corporation does not pay dividends to its shareholders.
Institutional asset management giants—such as Vanguard Group and BlackRock—alongside top corporate insiders and founding executives, hold the largest cumulative equity blocks in Moderna, Inc.
Determining whether Prothena Corporation (NASDAQ: PRTA) is a buy or a sell depends entirely on an investor's tolerance for clinical-stage biotechnology risk.
PRTA is the official Nasdaq stock ticker symbol representing Prothena Corporation plc, a clinical-stage biopharmaceutical company incorporated in Ireland.
Prothena generates revenue primarily through strategic research collaborations and licensing agreements with major global pharmaceutical companies (such as Roche, Novo Nordisk, and Bristol Myers Squibb).
ProHEALTH Care Associates operates as a large medical management and physician practice network in New York.
The major shareholder roster of Prothena includes prominent institutional asset managers and specialized biotech funds, featuring ECOR1 Capital LLC, FMR LLC (Fidelity), Rubric Capital Management, and BlackRock, which collectively hold dominant contro...
Prothena maintains a stable financial runway for a clinical-stage biotech firm, supported by hundreds of millions of dollars in cash reserves, zero long-term debt, and periodic upfront collaboration milestone payments injected by major global pharmac...
Whether PRTA is a suitable purchase depends heavily on an investor's appetite for clinical trial risks and biotech volatility.
The single largest institutional block and major shareholder holding in Prothena is managed by specialized biotechnology investment funds and asset management entities, most notably ECOR1 Capital LLC, alongside large institutional asset managers like...
Prothena maintains a solid cash preservation strategy, ending recent quarters with roughly $289 million in cash and cash equivalents and zero debt, bolstered by disciplined research and development spending, milestone injections from partners like No...
Prothena's trailing twelve-month revenue stands at approximately $57.
Prothena's stock price history has been characterized by sharp, event-driven volatility typical of clinical-stage biotech enterprises.
Prothena competes within the specialized biotechnology and drug discovery sector against peers focused on neurodegenerative disorders, protein dysregulation, and rare amyloid diseases, including clinical-stage and commercial biopharmaceutical innovat...
Prothena Corporation (NASDAQ: PRTA) carries a stock beta coefficient of approximately 0.
Prothya Biosolutions is a major European plasma-derived medicinal products organization.